Wednesday , October 18 2017
Home / Letter From The Editor (page 11)

Letter From The Editor

Nov. 22, 2016

dave

On Monday, the FDA gave approval to NovoNordisk’s new combination product, Xultophy. This is a combination of the super long-acting insulin degludec and the once daily GLP-1 agonist Liraglutide. The fixed dose combination is given in one to 50 dosing steps to maximize to glycemic control. The super long-acting insulin ...

Read More »

Nov. 19, 2016

dave

Recently I got to spend some time with the director of a kidney / liver transplant center in Largo, Fl. While I was touring the facility she was telling me about how they select candidates for kidney transplant, and the problems that keep people from being selected. We also talked ...

Read More »

Nov. 17, 2016

dave

Many prescribers are seeing the benefits of using an SGLT-2 inhibitor with insulin in their patients, and in this month’s edition we have an article on the benefits of using these together. From a personal professional experience, I have first hand knowledge of how that works as you can see ...

Read More »

Nov. 15, 2016

dave

This past week, I received a packet of new information on managing diabetes. It was provided by a pharma company and developed by one of the most prestigious diabetes education centers in the world. This was a packet that we could share with our diabetes patients, so they could manages ...

Read More »

Nov. 12, 2016

dave

A lot of our readers get into diabetes care because of a personal or family association with the disease. I did just the opposite. When our publisher, Steve Freed, got me involved 20 years ago I had no connection to the disease, but as the years have gone by, I ...

Read More »

Nov. 8, 2016

dave

Last week I visited a former patient of mine who was in the hospital, for a bike-related accident. He wasn’t coming down a hill at 45mph or trying to jump over a stump with a mountain bike. He was simply riding his townie cruiser on a bike trail when he ...

Read More »

Nov. 5, 2016

Before you even begin reading this week’s edition, you need to get out a pair of running shoes, walking shoes, stretchy bands, weights and a sweatband. Well, not really, but your patients may want to at least try to use a couple of those based on the information we have ...

Read More »

Nov. 1, 2016

dave

There have been three new classes of diabetes drugs that have changed the face of diabetes care over the past 7 years. Two of those are oral and one is an injectable, and they have been going head to head all that time. Now, rather than comparing them, clinicians are ...

Read More »

Oct. 29, 2016

dave

Many times there are presentations at medical conferences that seem to be the same old information refashioned, or they are so far-fetched that no one pays attention to them. If we look back, we oftentimes see that which seemed far-fetched years ago is common practice now. A good example of ...

Read More »

Oct. 25, 2016

dave

Glucagon gets a lot of mentions when we talk about diabetes. We take metformin to stop glucagon release; we inject glucagon when a patient is so hypoglycemic they are passed out. We even use glucagon-like peptide to treat diabetes. But exactly what is glucagon, where does it come from, and how ...

Read More »